Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2361]

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early...

Dr Edith Perez - Mayo Clinic, Rochester, USA

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early- stage HER2-positive breast cancer ( Dr Edith Perez - Mayo Clinic, Rochester, USA )

ASCO 2014: Advances in prostate cancer discussion

Prof Noel Clarke; Dr Cora Sternberg; Dr Kurt Miller, Prof Wysocki

ASCO 2014: Advances in prostate cancer discussion ( Prof Noel Clarke; Dr Cora Sternberg; Dr Kurt Miller, Prof Wysocki )

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early...

Dr Edith Perez - Mayo Clinic, Rochester, USA

Adding lapatinib to adjuvant trastuzumab does not improve outcomes in early-stage HER2-positive breast cancer ( Dr Edith Perez - Mayo Clinic, Rochester, USA )

Adjuvant exemestane more effective than tamoxifen when combined with ovarian...

Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona...

Adjuvant exemestane more effective than tamoxifen when combined with ovarian function suppression in young women with hormone-sensitive, early-stage breast cancer ( Dr Olivia Pagani - Oncology Institute of Southern Switzerland, Bellinzona, Switzerland )

Targeted drug combo, cediranib plus olaparib, significantly increases...

Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA

Targeted drug combo, cediranib plus olaparib, significantly increases progression-free survival in recurrent ovarian cancer ( Dr Joyce Liu - Dana-Farber Cancer Institute, Boston, USA )

Lenvatinib yields high response rates and delays progression in radioiodine...

Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France

Lenvatinib yields high response rates and delays progression in radioiodine-resistant, advanced differentiated thyroid cancer ( Prof Martin Schlumberger - Institut Gustave Roussy, Villejuif, France )

Second-line treatment with ramucirumab plus docetaxel extends survival in...

Dr Maurice Pérol - Centre Léon Bérard, Lyon, France

Second-line treatment with ramucirumab plus docetaxel extends survival in advanced NSCLC ( Dr Maurice Pérol - Centre Léon Bérard, Lyon, France )

Emerging pathways in immunotherapy

Prof Christopher Höller - Medical University of Vienna, Vienna, Austria

Emerging pathways in immunotherapy ( Prof Christopher Höller - Medical University of Vienna, Vienna, Austria )

Checkpoint blockade: a concept or already a reality?

Prof Paolo Ascierto - National Cancer Institute 'Foundazione G. Pascale'...

Checkpoint blockade: a concept or already a reality? ( Prof Paolo Ascierto - National Cancer Institute 'Foundazione G. Pascale', Naples, Italy )

Cancer evasion of the immune system: the fundamentals

Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland

Cancer evasion of the immune system: the fundamentals ( Prof Pedro Romero - Ludwig Institute for Cancer Research, Lausanne, Switzerland )

Upcoming trends in myeloma therapy

Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson

Upcoming trends in myeloma therapy ( Dr Kenneth Anderson; Prof Gareth Morgan; Prof Paul Richardson )

Recent advances in mantle cell lymphoma: Expert panel discussion

Prof Simon Rule; Prof Umberto Vitolo; Prof Pier Luigi Zinzani; Prof Emanuele...

Recent advances in mantle cell lymphoma: Expert panel discussion ( Prof Simon Rule; Prof Umberto Vitolo; Prof Pier Luigi Zinzani; Prof Emanuele Zucci )

More from ecancer